Cormorant Asset Management’s Beam Therapeutics BEAM Stock Holding History

Cormorant Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-90,045	Closed	-$5.16M	–	81
2022 Q1	$5.16M	Sell	90,045 -409,955	-82%	-$26.9M	0.4%	50
2021 Q4	$39.8M	Buy	500,000 +400,000	+400%	+$34.2M	2.37%	12
2021 Q3	$8.7M	Hold	100,000	–	–	0.35%	56
2021 Q2	$12.9M	Sell	100,000 -71,775	-42%	-$5.72M	0.44%	53
2021 Q1	$13.7M	Sell	171,775 -752,474	-81%	-$71.6M	0.31%	62
2020 Q4	$75.5M	Buy	924,249 +127,821	+16%	+$6.29M	1.8%	16
2020 Q3	$19.6M	Sell	796,428 -1	-0%	-$25	0.75%	38
2020 Q2	$22M	Hold	796,429	–	–	0.84%	38
2020 Q1	$14.3M	Buy	+796,429	New	+$17.3M	0.67%	44

Other funds holding BEAM

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Cormorant Asset Management's BEAM Position: Q2 2022 in Review

Cormorant Asset Management sold out of Beam Therapeutics (BEAM) in Q2 2022, closing a stake of 90,045 shares — an estimated $5.16M sold.

Cormorant Asset Management first reported a position in BEAM in Q1 2020 and held it in 9 quarters. The position peaked at $75.5M in Q4 2020. 205 funds tracked by Wall St. Rank hold BEAM as of Q2 2022.

Cormorant Asset Management reported no remaining Beam Therapeutics position as of Q2 2022 after selling out during the quarter.
Cormorant Asset Management sold 90,045 Beam Therapeutics shares in Q2 2022, an estimated $5.16M.
Cormorant Asset Management first reported a position in Beam Therapeutics in Q1 2020 and held it in 9 quarters.
Cormorant Asset Management's Beam Therapeutics position peaked at $75.5M in Q4 2020.
205 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2022.

Based on Cormorant Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.